Victory Capital Management Inc. Has $10.17 Million Stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Victory Capital Management Inc. raised its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 9.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 851,512 shares of the company’s stock after buying an additional 76,720 shares during the quarter. Victory Capital Management Inc. owned about 1.49% of Olema Pharmaceuticals worth $10,167,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Ensign Peak Advisors Inc grew its holdings in Olema Pharmaceuticals by 6.1% during the second quarter. Ensign Peak Advisors Inc now owns 14,849 shares of the company’s stock valued at $161,000 after purchasing an additional 850 shares during the period. California State Teachers Retirement System grew its holdings in shares of Olema Pharmaceuticals by 3.4% in the 1st quarter. California State Teachers Retirement System now owns 34,695 shares of the company’s stock valued at $393,000 after buying an additional 1,132 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Olema Pharmaceuticals by 6.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 26,251 shares of the company’s stock valued at $298,000 after buying an additional 1,486 shares in the last quarter. ClariVest Asset Management LLC raised its stake in Olema Pharmaceuticals by 3.1% during the 2nd quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company’s stock worth $683,000 after buying an additional 1,881 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Olema Pharmaceuticals by 67.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,014 shares of the company’s stock worth $132,000 after acquiring an additional 4,442 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Olema Pharmaceuticals Stock Down 5.0 %

NASDAQ:OLMA opened at $8.28 on Thursday. The company has a market cap of $474.43 million, a P/E ratio of -3.78 and a beta of 2.02. Olema Pharmaceuticals, Inc. has a twelve month low of $8.12 and a twelve month high of $16.77. The business has a 50 day moving average price of $11.77 and a two-hundred day moving average price of $11.93.

Analyst Upgrades and Downgrades

OLMA has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Wednesday, November 13th. Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday, August 7th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Olema Pharmaceuticals currently has an average rating of “Buy” and an average price target of $27.00.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.